PLx Pharma — Investor Presentation (May 2017)
21 slides from PLx Pharma's investor presentation, May 5, 2017
Slide 1: PLx Pharma Inc. Corporate Presentation
@) PLx Pharma Inc. Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes or incorporates by reference statements that consti 27h of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. These statements relate to future events or to our future financial performance, and inv
Slide 3: PLx Pharma Now Public: Broad Vision, Focused Strategy
Completed reverse merger with Dipexium Pharmaceuticals, Inc. ~ $12 million cash at closing, changed name to PLx Pharma Inc., ticker to PLXP and continued NASDAQ Capital Markets listing PLx Pharma Now Public Broad Vision, Focused Strategy Improve safety and efficacy of selected existing oral NSAIDs a
Slide 4: Management Team
ichael (Mike) J. Valentino 35+ years public and private CEO and senior management with successful OTC and Rx brands Executive Chairman of the Board =. Led Adams and OTC brand, Mucinex®, which achieved a “$2.3 bi id Global Head of Consumer Pharmaceuticals for Novartis AG ), RéShiratory is y Pharmacia
Slide 5: Independent Board of Directors
Independent Board of Directors Name Experience Gary S. Balkema + Former global head of Bayer Healthcare LLC and Worldwide Consumer Care Division ‘At Bayer USA repositioned aspirin after ten year decline into a growing business Prior to Bayer was VP and General Manager for American Cyanamid Co.'s Led
Slide 6: Targeting an Unmet Medical Need with Aspertec
Targeting an Unmet Medical Need with Aspertec™ * Aspirin is one of the most common NSAIDs (nonsteroidal anti-inflammatory drugs) available today and is widely used for treatment and prevention of cardiovascular disease * Approximately 34% of the United States population (107mm)' falls within categor
Slide 7: Why Does EC Aspirin Induce Gastric Ulceration?
Why Does EC Aspirin Induce Gastric Ulceration? Unidirectional Protection Somachi Gastroduodenal Reflux EC Aspirin Tablet Intact in Stomach (pH 3): No initial surface injury Duodenum EC Aspirin Disintegrates in Duodenum (pH 5.5): Free aspirin refluxes back into stomach GB) Result Free Aspirin Refluxe
Slide 8: Aspertec Clinically Demonstrates Better Absorption and Antiplatelet Efficacy than EC Aspirin
Aspertec™ Clinically Demonstrates Better Absorption and Antiplatelet Efficacy than EC Aspirin Comparison of Single Dose Aspirin Absorption Incidence of Complete Aspirin Response 2000 90.0% 83.6% 3 —® Aspertec™ %ot 80.0% 4 a ‘ 1500 EC Caplet patients 79.9% = with £ complete 90.0% S = 100 aspirin 50.0
Slide 9: Aspertec: Intended To Be More Reliable and Predictable than EC Aspirin
Aspertec™: Intended To Be More Reliable and Predictable than EC Aspirin Aspirin Antiplatelet Response Hazard Ratio (95%Cl) seouent Index Period ——_@—___ <0. 11 days — P <0.0001 4 days r 7 r r 1 4 2 0 2 4 6 8 10 <——_ ———-> EC Aspirin Better arate Aspertec™ Better PL-ASA-006 ™ PL-ASA-004 Aspertec™ 325
Slide 10: Aspertec Has Better GI Safety
Aspertec™ Has Better GI Safety Aspirin's Surface Injury 14.0% * Aspirin induces corrosive damage by direct contact with the gastric surface - manifested as 12.0% ulceration and bleeding ies Endoscopy demonstrates EC aspirin is not GI Shotpatients 8.0% p=0.004 safer, with no difference in ulcer risk
Slide 11: Unlocking Aspirin's Full Potential
: Unlocking Aspirin’s Full Potential ‘aan Differentiated Marketing Claims ————————_ * 3-5 times greater chance of complete antiplatelet effect than EC aspirin * In head-to-head clinical trials with EC aspirin, Aspertec™ provided faster acting, more reliable, predictable and sustainable antiplatelet
Slide 12: Aspertec Market Opportunity: High Risk Patients
Aspertec™ Market Opportunity: High Risk Patients Aspertec™ Initially Targets Four Sizeable U.S. Patient Populations Secondary Coronary Artery Disease (“CAD”) Prevention Secondary Stroke iabetes with >1 Risk | High Risk Primary Patients” Factor”) Prevention Patients who have previously Patients who h
Slide 13: Pricing - Potential Strategy
Pricing - Potential Strategy Aspertec™ Proposed Pricing: Premium and Value: $0.75 per capsule for 325 mg and 81 mg ($22.50/month at retail) — Higher margin and more profitable for retail trade compared to other OTC aspirin, including store brands — Fits well with wellness/loyalty program efforts for
Slide 14: Physicians Indicate High Intent to Prescribe Aspertec
Physicians Indicate High Intent to Prescribe Aspertec™ * Quantitative and qualitative research completed with >1,000 cardiologists, interventional cardiologists, neurologists, endocrinologists/diabetologists and 2,000 consumers Aspirin Therapy Prescribers Endocrinologists Cardiologists Neurologists
Slide 15: How Doctors Would Prescribe Aspertec
How Doctors Would Prescribe Aspertec™ Aspirin Therapy Prescribers Endocrinologists Cardiologists Neurologists _ Diabetologists Number of Physicians: 201 100 100 104 jp ee a Patients who have had a I I cardiovascular incident/heart 83% 78% 87% | 83% attack ! ; 1 t Patients who have had a cerebral 171
Slide 16: Positioning Aspertec as the Standard of Care
Positioning Aspertec™ as the Standard of Care * Reason to Believe: — Faster acting than EC aspirin Potential to be — Clinically superior antiplatelet efficacy © Best-in-class for than EC aspirin Acute Corona — Better acute GI safety when initiating Syndrome (ACS) dual antiplatelet therapy ¢ Market S
Slide 17: National Launch: Target Audiences
National Launch: Target Audiences Physician specialists * 33,000 physicians - Highly targetable specialty universe: Cardiologists, Neurologists, Endocrinologists/Diabetologists * Top 3-5 Deciles write 75-85% of all prescriptions * Total Targets: 12,000 - 15,000 physician specialists * Field reps are
Slide 18: Recent and Upcoming Milestones
Recent and Upcoming Milestones Aspertec™ 325 mg approved by FDA Successfully completed head-to-head clinical studies of Aspertec™ 325 mg against EC aspirin Aspertec™ brand name approved by the FDA First antiplatelet clinical study (PL-ASA-004) published in the Journal of the American College of Card
Slide 19: PLx Platform Technology: Product Pipeline
PLx Platform Technology: Product Pipeline Aspertec™, 325 mg OTC Pain and Fever Physician-directed (Cardiovascular Disease Prevention & Rheumatologic) Aspertec™, 81 mg as OTC Pain and Fever sNDA to be filed in Physician-directed (Cardiovascular Disease 2017 Prevention & Rheumatologic) FDA Approved GI
Slide 20: Strong Intellectual Property Protection Through 2032
Strong Intellectual Property Protection Through 2032 44 Issued Patents for Composition of Matter, Methods to Make, Methods of Use Drugs & Lipids: NSAIDs only ~The University of Texas (UT) License: PLx wholly owned composition and methods to make Claims for NSAIDs and lipid oils to enhance Gl safety
Slide 21: Conclusion
Conclusion Broad Vision, Focused Strategy Improve safety and efficacy of selected existing oral NSAIDs and other drugs — beginning with aspirin and ibuprofen — platform technology Novel PLxGuard™ delivery system utilizes surface acting lipids to selectively release Technology drugs in targeted porti